SavedAdd your journal

Journals / Anatolian Current Medical Journal / 2023 / Cilt: 5 Sayı: 4

The effect of direct-acting antivirals (DAA) on confirmed noninvasive fibrous parameters in chronic hepatitis C patients

Dilek BULUT
Merve Sefa SAYAR
Ali ACAR
Pages
426–431
Publication Date
2023-10-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: The confirmed noninvasive fibrous parameters used in the treatment of CHC are useful in evaluating the results of the treatments applied.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract: Objectives: Chronic hepatitis C (CHC) is an important public health problem in terms of the number of people it affects worldwide and the diseases it causes.
📊
Key Findings & Data:The high sustained virological response (SVR) rates achieved by the use of direct-acting antiviral (DAA) drugs in the recent period have shown that a new era has begun in this disease.
💡
Conclusion & Impact:Conclusions: The confirmed noninvasive fibrous parameters used in the treatment of CHC are useful in evaluating the results of the treatments applied.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Chronic hepatitis C · direct-acting antiviral agents · sustained virological response

Abstract

Abstract: Objectives: Chronic hepatitis C (CHC) is an important public health problem in terms of the number of people it affects worldwide and the diseases it causes. The high sustained virological response (SVR) rates achieved by the use of direct-acting antiviral (DAA) drugs in the recent period have shown that a new era has begun in this disease. It was aimed to evaluate the effect of DAAs on confirmed noninvasive fibrous parameters together with their effectiveness. Methods: 75 patients who were started on DAA treatment for CHC were included in the study. In addition, laboratory parameters values at the beginning of the treatment, 12 and 24 weeks after the end of the treatment, hepatitis C virus ribonucleic acid (HCV RNA) results and Aminotransferase-to-Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4) scores were compared. Results: The most common comorbidity in patients is hypertension (HT), and the most common source of transmission is surgical operations. Genotype 1b was the dominant genotype. The SVR rates of all patients 12 and 24 weeks after the end of treatment were 100%. The APRI and FIB-4 scores of the patients decreased significantly at the 12th and 24th weeks at the end of the treatment compared to the beginning of the treatment. Conclusions: The confirmed noninvasive fibrous parameters used in the treatment of CHC are useful in evaluating the results of the treatments applied.

🔖

Cite This Article

BULUT, D., SAYAR, M. S., ACAR, A. (2023). The effect of direct-acting antivirals (DAA) on confirmed noninvasive fibrous parameters in chronic hepatitis C patients. Anatolian Current Medical Journal, Cilt: 5 Sayı: 4, 426–431. https://ajindex.com/articles/968517

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):45-57.
  2. Singal AG, Volk ML, Jensen D, Bisceglie AMD, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280-288. e1. Ryder S. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53(3):451-455.
  3. Ozturk-Cerik H, Esen S, Altintas-Oner B, Celik M, Ozdemir T, Tanyel E. Evaluation of the effectiveness of direct-acting antiviral agents in patients with hepatitis C/hepatit C hastalarinda dogrudan etkili antiviral ilaclarin etkinliginin degerlendirilmesi. KLIMIK J. 2020;33(3):297-307.
  4. Tachi Y, Hirai T, Toyoda H, et al. Predictive ability of laboratory indices for liver fibrosis in patients with chronic hepatitis C after the eradication of hepatitis C virus. PLoS One. 2015;10(7):e0133515. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526.
  5. Chan J, Gogela N, Zheng H, et al. Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment. Digest Dis Sci. 2018;63(2):486-492.
  6. Li W, Liang J, An J, et al. Geographic distribution of HCV genotypes and efficacy of direct-acting antivirals in chronic HCV-infected patients in North and Northeast China: a real-world multicenter study. Canad J Gastroenterol Hepatol. 2022;2022:7395506. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211-21.
  7. Bulut ME, Topalca US, Murat A, et al. HCV genotype distribution of patients with chronic hepatitis C in İstanbul. Sisli Etfal Hastan Tip Bul. 2021;55(1):86. Çetin Duran A, Kibar F, Çetiner S, Yaman A. Determination of hepatitis C virus genotype and HCV infection transmission routes in Cukurova University Medical Faculty Hospital. Turk Hij Den Biol Derg. 2017;74(3):201-210. Alter MJ. Epidemiology of hepatitis C virus infection. WJG. 2007;13(17):2436. Karaca Ç, Çakaloğlu Y, Demir K, et al. Risk factors for the transmission of hepatitis C virus infection in the Turkish population. Dig Dis Sci. 2006;51(2):365-369.
  8. Azmi AN, Tan S-S, Mohamed R.